Calendario›LQDA›L606 · Re-Spire
L606 · Re-Spire
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Ensayo de Liquidia Corp en Hipertension pulmonar debida a enfermedad pulmonar (trastorno).
- Fase
- Fase 3
- Estado
- Reclutando pacientes
- Participantes
- 344
- Centros
- 36
- Fin del objetivo primario
- jul 2029
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en abr 2026.
Qué mide
Cambio desde el valor basal en la distancia recorrida en 6 minutos (6MWD) evaluada mediante la prueba de marcha de 6 minutos (6MWT) (16 semanas)
Qué se prueba
Se estudia si L606 ayuda a personas con hipertension pulmonar causada por enfermedad pulmonar intersticial, comparandolo con placebo.
Lo que dice el documentofind out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test").
Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.
Más ensayos de LQDA
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| L606 inhalation suspension | Fase 3 | En marcha, sin reclutar | mar 2025 (real) |
| LIQ861 Inhaled Treprostinil | Fase 3 | En marcha, sin reclutar | may 2025 (prevista, ya pasada: sin actualizar en el registro) |
| LIQ861 · RE-WARM | Fase 2 | Aún sin reclutar | feb 2027 (prevista) |
| LIQ861 | Fase 4 | Aún sin reclutar | may 2027 (prevista) |
| LIQ861 · ASCENT | no aplica | Reclutando pacientes | jul 2027 (prevista) |
| Inhaled dry powder treprostinil | Fase 2 | Interrumpido | dic 2020 (real) |
Todos los de LQDA, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07285655), actualizada en ago 2026.